GGrantIndex
← Search

GENE EXP. AND GENOTYPING

$381,557P30FY2009CANIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications, trials & patents

Trial NCT05340673Trial NCT05198830Trial NCT02590107Trial NCT02535325Trial NCT02451124Trial NCT02419846Trial NCT02417948Trial NCT02392377Trial NCT02388932Trial NCT02383433Trial NCT02375477Trial NCT02354326Trial NCT02345460Trial NCT02342730Trial NCT02337465Trial NCT02327390Trial NCT02319889Trial NCT02307474Trial NCT02287636Trial NCT02252393Trial NCT02181478Trial NCT02179762Trial NCT02163317Trial NCT02158767Trial NCT02153450Trial NCT02135562Trial NCT02131207Trial NCT02129582Trial NCT02129569Trial NCT02129517Trial NCT02129218Trial NCT02128373Trial NCT02108587Trial NCT02100423Trial NCT02084147Trial NCT02082405Trial NCT02081794Trial NCT02079155Trial NCT02073097Trial NCT02073045Trial NCT02071901Trial NCT02070458Trial NCT02070419Trial NCT02055586Trial NCT02037048Trial NCT01973062Trial NCT01959490Trial NCT01959477Trial NCT01954784Trial NCT01954732Trial NCT01951885Trial NCT01939028Trial NCT01928485Trial NCT01894061Trial NCT01408043Trial NCT00991991Trial NCT00970684Trial NCT00961220Trial NCT00956475Trial NCT00952939Trial NCT00949247Trial NCT00945061Trial NCT00941720Trial NCT00941070Trial NCT00939510Trial NCT00918892Trial NCT00918788Trial NCT00918658Trial NCT00918216Trial NCT00910039Trial NCT00909662Trial NCT00908739Trial NCT00908141Trial NCT00907699Trial NCT00905086Trial NCT00900133Trial NCT00899158Trial NCT00899132Trial NCT00898573Trial NCT00898274Trial NCT00897143Trial NCT00892385Trial NCT00873600Trial NCT00873002Trial NCT00866320Trial NCT00856115Trial NCT00853021Trial NCT00842452Trial NCT00809185Trial NCT00796978Trial NCT00795678Trial NCT00769951Trial NCT00769249Trial NCT00752323Trial NCT00740961Trial NCT00736216Trial NCT00735514Trial NCT00733252Trial NCT00732745Trial NCT00732173

Abstract

The mission of the Gene Expression and Genotyping Facility (GEGF) is to facilitate implementation of high throughput genetic technologies for the research conducted by members of the Case community. The GEGF serves as a technical and consulting resource for Cancer Center members, as well as other investigators who have laboratories at Case Western Reserve University, University Hospitals of Cleveland, the Cleveland Clinic Foundation, the VA Hospital, and MetroHealth Hospital in the areas of high throughput expression analysis and genotyping. It is the only facility of its capability in Cleveland. This facility utilizes Affymetrix and Applied Biosystems (ABI) technologies to provide global and quantitative (on user-identified genes) gene expression analysis services. A diverse array of Affymetrix and ABI technologies are available to address a spectrum of genotyping needs, including whole genome scans, custom designed fine-mapping studies involving 3,000-10,000 SNPs and interrogation of small numbers (<100) of specific SNPs in thousands of samples. The core operates in a full-service mode with staff providing initial consultation, executing the chemistry, carrying out the analysis, and offering data trimming and data interpretation services. To carry out these technologies, the GEGF has 14 computers, an Affymetrix Workstation dedicated to data generation, 3 fluidics stations, 2 hybridization ovens and a GC3000 scanner with autoloader. ABI equipment includes a 7,900 Sequence Detection System, with a barcode reader, robotics allowing the capability to process 5,000 sample wells per day, and the modules for processing Low Density Arrays, 96- and 384-well plates. The GEGF also has 5 GeneAMP ABI 9700 PCR machines, with 96- &384-well block capability and an ABI 6100 Nucleic Acid Prep Station. For PCR-based assays, the GEGF established an amplicon-free room, containing 2 PCR hoods, dedicated pipettors, small microfuges and minithermocyclers. Additional equipment includes: 2 Matrix robotic liquid handling systems, the PlateMate 2x2 (X-Y stage movement) and the PlateMate Plus (allows rapid reconfiguration from 96- to 384-well format), dedicated centrifuges, an Agilent Bioanalyzer and a NanoDrop Spectrophotometer, which quantifies nucleic acids in 1-2 ul samples. Turn-around time for sample preparation and analysis is <10 days for average size projects and satisfactory timetables are established for large projects during initial consultations. Cancer Center members receive a 35% discount on all GEGF provided services. The core has steadily grown from its inception in 2000, when we had 22 users and a single full-time staff member to its current staff of 51/2 and 142 registered users. Approximately 60 investigators use the GEGF every year and 30-50% of these are first time users, documenting that the GEGF continues to enjoy a healthy level of growth and a robust level of sustained work with repeat users. Finally, the GEGF has provided services for members from 8 of the Cancer Center's programs, and has played a role in securing more than 33 grants awarded to Cancer Center members.

View original record on NIH RePORTER →